Extracellular vesicles (EVs) are nano‐scale structures produced by cells that transport biological substances for intercellular communication. The tetraspanins CD9, CD81, and CD63 are crucial to EV biogenesis and function. This study uses CRISPR‐Cas9 system to knock out (KO) CD9, CD63, and CD81 in HEK293T cells. The goal is to investigate the role of these tetraspanins in EV bioengineering with the hypothesis that repressing endogenous production may increase the availability of exogenously introduced tetraspanin‐fusion constructs and increase engineered EV production. First, it is observed that individually knocking out a tetraspanin does not significantly affect EV formation. However, when all three tetraspanins are simultaneously knocked out, there is a marked decrease in EV production, as measured by nanoparticle tracking analysis. Second, upon reintroduction of the corresponding tetraspanins fused to firefly ThermoLuc or neon green into the PanKO‐, CD9KO‐, CD63KO‐, and CD81KO‐cells, the engineered EVs display a significant increase in production by 50% to 70% compared to transduction of wild‐type cells, as measured by luminometer and imaging flow cytometry. These findings emphasize the potential of tetraspanin KO in the bioengineering of EVs, paving the way for new therapeutic applications by enhancing production and potentially modifying their cargo.
Mamand et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: